Skip to main content

Table 5 Comparison of participants who were still on treatment or transferred out (n = 12,873) compared to those included in the final outcomes analysis (n = 170,017)

From: Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa

Characteristics Excludeda
N = 12873
Included
N = 170017
Age at start of treatment (years) <10 (children) 875 (6.80%) 17384 (10.22%)
10–14 (young adolescents) 120 (0.93%) 1912 (1.12%)
15–19 (older adolescents) 250 (1.94%) 3681 (2.17%)
20–24 (young adults) 945 (7.34%) 10741 (6.32%)
25–49 (adults) 9226 (71.67%) 114137 (67.13%)
≥50 (older adults) 1457 (11.32%) 22162 (13.04%)
District in Gauteng Ekurhuleni Metropolitan Municipality 4385 (34.06%) 59919 (35.24%)
City of Johannesburg 8488 (65.94%) 110098 (64.76%)
Registration year 2010 3223 (25.04%) 29481 (17.34%)
2011 2301 (16.29%) 29698 (17.47%)
2012 2097 (16.29%) 28747 (16.91%)
2013 2094 (16.27%) 28778 (16.93%)
2014 1845 (14.33%) 27661 (16.27%)
2015 1313 (10.20%) 25652 (15.09%)
Sex Female 5953 (46.24%) 76388 (44.93%)
Case definitionb Bacteriologically confirmed 8720 (67.74%) 117640 (69.19%)
Clinically diagnosed 2110 (16.39%) 27548 (16.20%)
  Missing/Unknown 2043 (15.87%) 24829 (14.60%)
Full case definition Xpert MTB/RIF 1400 (10.88%) 27082 (15.93%)
  Smear microscopy 6377 (49.54%) 80815 (47.53%)
  Culture 429 (3.33%) 5209 (3.06%)
  Aspiration/biopsy 389 (3.02%) 3534 (2.08%)
  CSF 125 (0.97%) 1000 (0.59%)
  X-ray 1848 (14.36%) 21872 (12.86%)
  Skin Test 262 (2.04%) 5676 (3.34%)
  Unknown clinical diagnosis 2043 (15.87%) 24829 (14.60%)
Patient category New Patient 11740 (91.20%) 160512 (94.41%)
Previously treated 792 6667
   Relapse 534 (4.15%) 4693 (2.76%)
   Re-treatment after failure 91 (0.71%) 719 (0.42%)
   Re-treatment after LTFU (default) 167 (1.30%) 1255 (0.74%)
Unknown previous TB treatment history 341 (2.65%) 2838 (1.67%)
Classification of Disease Pulmonary TB 9877 (76.73%) 142843 (84.02%)
EPTB 2996 (23.27%) 27174 (15.98%)
Smear status at initiation Positive 4298 (33.39%) 63984 (37.63%)
Negative 3261 (25.33%) 40547 (23.85%)
Missing 5314 (41.28%) 65486 (38.52%)
HIV status Positive, on ART 4550 (35.35%) 66871 (39.33%)
Positive, not on ART 2608 (20.26%) 27149 (15.97%)
Positive, ART status unknown 1565 (12.16%) 15583 (9.17%)
Negative 2092 (16.25%) 38692 (22.76%)
HIV status unknown 2058 (15.99%) 21722 (12.78%)
CD4 count (cells/mm3) if HIV positivec ≤100 2170 (16.86%) 23843 (14.02%)
101–250 1539 (11.96%) 18895 (11.11%)
251–350 441 (3.43%) 6244 (3.67%)
351–500 326 (2.53%) 4551 (2.68%)
>500 213 (1.65%) 3091 (1.82%)
Missing 8184 (63.57%) 113433 (66.70%)
Median (IQR) 126 (52–250) 113 (45–221)
Started on cotrimoxazole prophylaxis Yes 6570 (75.32%) 86984 (79.36%)
No 1237 (14.18%) 13535 (12.35%)
Missing/unknown 916 (10.50%) 9084 (8.29%)
Treatment regimen Regimen 1 (2 RHZE/4 RH) 11032 (85.70%) 146174 (85.98%)
Regimen 2 (2 RHZES/1 HRZE/5 HRE) 1063 (8.26%) 8301 (4.88%)
Regimen 3B (2 RHZE / 4 RH) 778 (6.04%) 15534 (9.14%)
Other 0 (0.00%) 8 (0.00%)
Treatment supervision (Intensive Phase) Yes 2356 (18.30%) 26814 (15.77%)
No 9205 (71.51%) 119911 (70.53%)
Missing 1312 (10.19%) 23292 (13.70%)
Treatment supervision (Continuation Phase) Yes 414 (3.22%) 7308 (4.30%)
No 11147 (86.59%) 139417 (82.00%)
Missing 1312 (10.19%) 23292 (13.70%)
Smear conversion at 2 monthsd Yes 185 (14.39%) 22291 (70.88%)
No 1101 (85.61%) 9160 (29.12%)
NA (Not smear positive at baseline or < 2 available smears) 8176 97894
Any smear conversione Yes 672 (36.60%) 55956 (95.06%)
No 1164 (63.40%) 2905 (4.94%)
NA (Not smear positive at baseline or < 2 available smears) 8176 97894
  1. Xpert MTB/RIF GeneXpert MTB/RIF, CSF cerebral spinal fluid, EPTB extra-pulmonary tuberculosis, LTFU loss to follow-up, HIV human immunodeficiency virus, ART antiretroviral therapy, IQR interquartile range
  2. aExcluded cases include those who were still on treatment at ten months, those who were lost to follow-up, and those with unknown outcomes
  3. bBacteriologically confirmed includes Xpert MTB/RIF, smear, or culture (and if aspiration/biopsy or cerebral spinal fluid (CSF) was listed, although the corresponding laboratory method was unknown). Clinically diagnosed includes X-ray and tuberculin skin test
  4. cReported for HIV positive patients only
  5. dSmear conversion at two months is two consecutive negative smears at least 30 days apart within two months of treatment initiation. One smear is sent monthly for smear microscopy
  6. eAny smear conversion is two consecutive negative smears at least 30 days apart at any time after treatment initiation. Ascertained at the end of treatment